Akari Market Capitalization from 2010 to 2024

AKTX Stock  USD 1.21  0.09  8.04%   
Akari Therapeutics Market Cap yearly trend continues to be fairly stable with very little volatility. Market Cap will likely drop to about 14.5 M in 2024.
Check Akari Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akari Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 6.4 M, Selling General Administrative of 7.6 M or Other Operating Expenses of 18 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Akari financial statements analysis is a perfect complement when working with Akari Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Akari Therapeutics Correlation against competitors.

Latest Akari Therapeutics' Market Capitalization Growth Pattern

Below is the plot of the Market Cap of Akari Therapeutics PLC over the last few years. It is Akari Therapeutics' Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akari Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 30.35 M10 Years Trend
Slightly volatile
   Market Cap   
       Timeline  

Akari Market Capitalization Regression Statistics

Arithmetic Mean889,730,843
Geometric Mean270,737,478
Coefficient Of Variation89.22
Mean Deviation744,616,402
Median1,095,123,605
Standard Deviation793,834,831
Sample Variance630173.7T
Range1.6B
R-Value(0.91)
Mean Square Error114164.3T
R-Squared0.83
Slope(161,889,469)
Total Sum of Squares8822432.4T

Akari Market Capitalization History

202414.5 M
202315.3 M
201929.3 M
2018496.3 M
20171.1 B

About Akari Therapeutics Financial Statements

Akari Therapeutics investors use historical fundamental indicators, such as Akari Therapeutics' Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Akari Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Akari Therapeutics, Plc is based in London, the United Kingdom. Akari Therapeutics is traded on NASDAQ Exchange in the United States.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.